Laser Therapy for Localized Prostate Cancer

Does laser therapy for localized prostate cancer mean fewer side effects? As a survivor of an incurable blood cancer, my life is all about long-term and late-stage side effects. PCa survivors also have to balance quantity of life with quality of life.

When men are diagnosed with localized prostate cancer, they are often presented with difficult treatment choices. Surgery and radiation can be effective, but they also carry risks that can permanently impact quality of life — including urinary incontinence, erectile dysfunction, and bowel complications.

In recent years, newer focal therapies have emerged that aim to destroy cancer while preserving as much healthy prostate tissue as possible. One of the most promising options is laser therapy, also known as focal laser ablation (FLA).

While laser therapy is not appropriate for every prostate cancer patient, it may offer an appealing middle ground between aggressive whole-gland treatment and active surveillance.

Let’s look at what laser therapy is, how it works, who may benefit, and what current research says.

Is Focal Therapy the solution to Prostate Cancer?

How Laser Therapy Works

During focal laser ablation:

MRI imaging identifies the tumor location.
A thin laser fiber is inserted into the prostate through the perineum (the area between the scrotum and rectum).
The laser delivers thermal energy directly into the tumor.
Heat destroys cancer cells while real-time MRI monitoring helps prevent damage to surrounding tissue.

Most procedures are performed on an outpatient basis, and recovery is typically faster than surgery or radiation.

Who May Be a Candidate for Laser Therapy?

Laser therapy is generally considered for men with:

• Localized prostate cancer confined to one area of the prostate
• Low-risk or intermediate-risk disease
• Visible tumor lesions identifiable on MRI
• Desire to preserve urinary and sexual function
• Preference to avoid surgery or radiation

It is less commonly recommended for men with:

• High-risk or aggressive prostate cancer
• Cancer spread throughout the prostate
• Metastatic disease

Patient selection is critical because focal therapy targets only known cancer sites rather than treating the entire prostate.

Potential Benefits of Laser Therapy

Reduced Risk of Urinary Incontinence

Whole-gland treatments can damage muscles controlling urinary continence. Laser therapy’s precision helps preserve these structures, reducing the likelihood of long-term leakage.

Lower Rates of Erectile Dysfunction

Because laser therapy avoids many nerve bundles surrounding the prostate, sexual function is often better preserved compared with radical prostatectomy or radiation therapy.

Faster Recovery

Many men return to normal activity within days rather than weeks or months.

Repeatable Treatment Option

If cancer returns, focal laser therapy can often be repeated or followed by other treatments if necessary.

Preserves Future Treatment Options

Laser therapy typically does not eliminate the possibility of surgery, radiation, or systemic therapies later if disease progression occurs.

Potential Risks and Side Effects

Although laser therapy is considered less invasive, it is not risk-free.

Possible side effects include:

• Temporary urinary frequency or urgency
• Mild discomfort or pelvic pain
• Short-term erectile dysfunction
• Prostate inflammation
• Urinary retention
• Rare infection or bleeding

Most side effects improve as inflammation and tissue healing progress.

The Importance of Imaging and Monitoring

Laser therapy relies heavily on advanced imaging. MRI plays a central role in:

• Diagnosing tumor location
• Guiding treatment
• Monitoring treatment success
• Detecting recurrence

Following treatment, patients typically undergo:

• PSA monitoring
• Follow-up MRI scans
• Periodic prostate biopsy in some cases

Active monitoring remains essential because focal therapy treats visible tumors but may miss microscopic disease.

What Does the Research Show?

Focal laser therapy remains an evolving treatment, but early and mid-term research has shown encouraging results.

Studies suggest:

• High rates of cancer control in properly selected patients
• Low rates of severe urinary incontinence
• Improved preservation of sexual function
• High patient satisfaction and quality of life

However, long-term data comparing laser therapy to surgery or radiation remains limited. Patients considering this approach should understand that focal therapy is still considered investigational in some medical settings.

Laser Therapy vs. Active Surveillance

Many men diagnosed with low-risk prostate cancer choose active surveillance, which involves regular monitoring without immediate treatment.

Laser therapy may appeal to men who:

• Feel anxious about leaving cancer untreated
• Have disease showing signs of progression
• Want treatment while minimizing side effects

Both options can be reasonable depending on tumor biology, patient preferences, and physician guidance.

Integrative Survivorship Considerations

Treating prostate cancer is only one part of survivorship. Supporting overall health, immune function, and inflammation control may help improve long-term outcomes.

Evidence-based survivorship strategies often include:

• Anti-inflammatory, plant-forward diet
• Regular exercise
• Weight management
• Stress reduction
• Cardiovascular health monitoring
• Hormonal balance evaluation

A comprehensive survivorship plan focuses on both cancer control and long-term quality of life.

Questions Patients Should Ask Before Choosing Laser Therapy

If you are considering focal laser ablation, discussing these questions with your treatment team may help:

• Am I a strong candidate based on tumor location and risk level?
• How many laser therapy procedures has my physician performed?
• What imaging will guide treatment?
• What follow-up testing will be required?
• If cancer returns, what are my future treatment options?
• What side effects should I realistically expect?

Please scroll down the page and post a question or a comment if you’d like. After all, knowledge is power.

Good luck

David Emerson

Cancer Survivor
Cancer Coach
Director PeopleBeatingCancer

Focal therapy using a novel cooled laser device for prostate cancer: early trial results

Abstract

Objectives

To determine the short-term oncological results and safety of the ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT-PC) trial, the first phase II clinical trial of ProFocal® (Medlogical Innovations, Sydney, Australia), a novel, cooled laser focal therapy (cLFT) device for prostate cancer (PCa) treatment.

Patients and Methods

Men with localised PCa, prostate-specific antigen (PSA) level ≤15 ng/mL, T stage ≤T2c, International Society of Urological Pathology (ISUP) score 2–3 concordant with multiparametric magnetic resonance imaging (mpMRI) visible disease were recruited for this trial (Australian and New Zealand Clinical Trial Registry [ACTRN]12618001774213p) at Nepean Hospital, Australia. The cLFT was performed under general anaesthesia as a day procedure. Primary outcome was adequacy of tissue ablation assessed by mpMRI within 72 h and biopsy at 3 months. Secondary outcomes of functional measures were assessed using validated questionnaires (International Prostate Symptom Score, Sexual Health Inventory for Men [SHIM], Expanded Prostate cancer Index Composite [EPIC], 12-item Short-Form Health Survey). Complications and adverse events within 90 days were reported using Clavien–Dindo classification grading.

Results

A total of 100 patients were recruited. The median (interquartile range [IQR]) age was 66 (60–72) years, PSA level 5.9 (3.9–7.6) ng/mL, prostate volume 39 (30–51) mL and MRI lesion volume 0.84 (0.57–1.2) mL. The median (IQR) treatment time was 60 (47–70) min. In all, 84% had no ISUP Grade Group ≥2 PCa in their 3-month treatment zone biopsies. Erectile dysfunction was reported in 12% of the men, with a 15% mean decline in the SHIM and EPIC-sexual domains scores. There was a 4.5% decrease on EPIC-urinary domain scores. There was no decline in any other functional measures. This study’s main limitations were the absence of a control group and the short follow-up.

Conclusions

The PFLT-PC trial demonstrates that at 3 months, cLFT using the ProFocal device provides an 84% treatment success with low morbidity.

laser therapy for localized prostate cancer laser therapy for localized prostate cancer